Acquired resistance often limits therapeutic efficacy of the BFAF (V600E) kinase inhibitor
PLX4032 in patients with advanced melanoma. Epitranscriptomic modification of mRNAs by N …

Methyltransferase-like 3 (METTL3) is the catalytic subunit of the N 6 -adenosine methyltransferase
complex responsible for N 6 -methyladenosine (m 6 A) modification of mRNA in …

IL-34 has been recently identified as a ligand for CSF1R that regulates various cellular processes
including cell proliferation, survival, and differentiation. Although the binding of IL-34 to …

The post-transcriptional processing of N 6-methyladenosine (m 6 A)-modified mRNA by YTH
domain-containing family protein 1 (YTHDF1) plays a crucial role in the regulation of gene …

The Hippo signaling pathway controls cellular processes including growth, homeostasis,
and apoptosis. The kinase STK3 acts upstream in this pathway to activate LATS1/2 kinase, …

Reversible N 6 -adenosine methylation of mRNA, referred to as m 6 A modification, has
emerged as an important regulator of post-transcriptional RNA processing. Numerous studies …

Background/Aim: The B-raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation
is frequent in patients with advanced melanoma. PLX4032, an inhibitor of BRAFV600E …

Simple Summary Members of the interleukin (IL)-1 cytokine family exhibit dual functions in
the regulation of inflammation and cancer. Recent studies have shown the critical role of IL-…

Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (PIN1) induces conformational and
functional changes to numerous key signaling molecules following proline-directed …

Purpose Nuclear accumulation of YAP/TAZ promotes tumorigenesis in several cancers,
including melanoma. Although the mechanisms underlying the nuclear retention of YAP are …